Prosecution Insights
Last updated: May 29, 2026

Examiner: FAY, ZOHREH ALEMZADEH

Tech Center 1600 • Art Units: 1612 1617 1621 1627 1629

This examiner grants 52% of resolved cases

Performance Statistics

51.8%
Allow Rate
-8.2% vs TC avg
1,172
Total Applications
-6.7%
Interview Lift
1189
Avg Prosecution Days
Based on 1103 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%
§101 Eligibility
7.2%
§102 Novelty
68.1%
§103 Obviousness
5.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17392837 CONSISTENCY OF CROP YIELD THROUGH BIOLOGICAL NITROGEN FIXATION Non-Final OA Pivot Bio, Inc.
19000196 GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEM Non-Final OA MEDISCA PHARMACEUTIQUE Inc.
17760990 HIGH DENSITY LIPOPROTEIN-LIKE NANOPARTICLES AS INDUCERS OF FERROPTOSIS IN CANCER Non-Final OA Northwestern University
17975485 COMPOSITIONS, ARTICLES, DEVICES, AND METHODS RELATED TO DROPLETS COMPRISING A CLOAKING FLUID Non-Final OA Massachusetts Institute of Technology
17800838 SUPRACHOROIDAL DELIVERY OF DRUG PARTICLES TO REDUCE TOXICITY Final Rejection The Johns Hopkins University
18025037 Medium for Tissue for Transplantation Non-Final OA Riken
17909601 STABILIZATION OF COMPOUNDS AS CYCLODEXTRIN COMPLEXES Final Rejection University of Pittsburgh - Of the Commonwealth System of Higher Education
17849545 BIOMIMETIC POLYMERIC COMPOSITE FOR HEART VALVE REPAIR Non-Final OA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
17640128 USE OF ENCAPSULATED STEROLS TO MODIFY GROWTH OF CROPS, CONTROL, AGRICULTURAL PESTS AND AS NON-TOXIC PRE-EMERGENT HERBICIDES Non-Final OA The Texas A&M University System
18417410 LIQUID PHARMACEUTICAL COMPOSITION Non-Final OA Verona Pharma Limited
18823760 NOVEL FORMULATION AND TREATMENT METHODS Non-Final OA PRODRUGXTEND PTY LTD
18281381 COSMETIC SKIN CARE COMPOSITION Non-Final OA Conopco, Inc., d/b/a UNILEVER
18007119 LYOPHILIZED FORMULATION CONTAINING CEPHALOSPORIN HAVING CATECHOL GROUP AND THE MANUFACTURING METHOD Final Rejection SHIONOGI & CO., LTD.
18578843 PHARMACEUTICAL COMPOSITIONS OF OZANIMOD Non-Final OA ZYDUS LIFESCIENCES LIMITED
17763010 SEED COATING COMPOSITIONS Non-Final OA CORN PRODUCTS DEVELOPMENT, INC.
18018108 Aqueous Composition Final Rejection Rohto Pharmaceutical Co., Ltd.
18292990 CONTROLLED RELEASE COATING AGENT Non-Final OA NUTRITION & BIOSCIENCES USA 1, LLC
18681706 OPHTHALMIC COMPOSITION FOR THE TREATMENT OF VISUAL DISORDERS Final Rejection FOODVICA, S.A. DE C.V.
18294487 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERHIDROSIS Non-Final OA Wayne Stephen ANDREWS
18579412 COATINGS, FORMULATIONS, USES AND COATING METHODS Non-Final OA BIOINTERACTIONS LTD
18578761 SACUBITRIL VALSARTAN SODIUM SUSTAINED-RELEASE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF Non-Final OA SHANGHAI AURORA BIOTECHNOLOGY CO., LTD.
18577404 MICELLE COMPLEX AND DRUG CARRIER COMPRISING SAME Non-Final OA DR. CURE CO., LTD.
18576610 ORAL COMPLEX TABLET COMPRISING SITAGLIPTIN, DAPAGLIFLOZIN, AND METFORMIN Non-Final OA HANMI PHARM. CO., LTD.
18574889 SEED UNIT COMPRISING CHARCOAL AND POLYMERIC SUPERABSORBENT Non-Final OA Schierbecker Handels GmbH & Co. KG
18555323 OPHTHALMIC TOPICAL COMPOSITION WITH CERIA NANOPARTICLES FOR TREATING DISEASES OF POSTERIOR SEGMENT OF THE EYE Non-Final OA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
18397155 PLANT BIOLOGIC INCLUDING PYRROLOQUINOLINE QUINONE (PQQ) Non-Final OA Dakota Bio LLC
18573953 COMPOSITIONS AND METHODS FOR VISION IMPROVEMENT Non-Final OA Azura Ophthalmics Ltd.
18571711 COMPOUND LIQUID FERTILIZER Non-Final OA Albert Nikolaevich DENISOV
18543825 MULTIFUNCTIONAL AGRICULTURAL ADJUVANT COMPOSITIONS Non-Final OA WinField Solutions, LLC
18560787 EXTENDED-WEAR SILICONE HYDROGEL CONTACT LENSES AND USES THEREOF Non-Final OA OCUMEDIC, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month